Kiichiro Toyoizumi

4PUBLICATIONS
41CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersInfectious diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Sep 15, 2026
Amivantamab plus pembrolizumab in previously untreated recurrent/metastatic head and neck squamous cell cancer: Results from the phase 1b/2 OrigAMI-4 study.

|May 31, 2026
Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study.

|Sep 02, 2022
Bias correction based on weighted likelihood for conditional estimation of subgroup effects in randomized clinical trials.

Kiichiro Toyoizumi, Shigeyuki Matsui

|Dec 11, 2019
Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens - The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study.

Matteo Bassetti, Mari Ariyasu, Bruce Binkowitz

Pageof 1

Frequent Collaborators

2 joint publications

Kevin J Harrington

2 joint publications

Mahadi Baig

2 joint publications

Paul L Swiecicki

2 joint publications

Emrullah Yilmaz